NGNEHealthcare · BiotechnologyThe 9 Wall Street analysts covering Neurogene, Inc. hold a median 12-month price target of $65 — +145.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Neurogene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NGNE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +145.3% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Canaccord Genuity | Maintains | Buy | $180 → $166 |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $69 → $81 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $65 |
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Feb 2026 | Canaccord Genuity | Initiates | Buy | — |
| 26 Jan 2026 | LifeSci Capital | Initiates | Outperform | — |
| 13 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2025 | Craig-Hallum | Initiates | Buy | — |
| 12 June 2025 | BMO Capital | Maintains | Outperform | — |
| 20 May 2025 | BMO Capital | Maintains | Outperform | — |
| 16 May 2025 | Baird | Downgrade | Neutral | — |
| 13 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Apr 2025 | BMO Capital | Maintains | Outperform | — |
| 25 Mar 2025 | Baird | Maintains | Outperform | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NGNE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Neurogene, Inc. returned +2.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 46% of US stocks
Cheaper than 74% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Neurogene, Inc. has a market value of $517.7M and an enterprise value of $292.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$111.1M.
Free cash flow in the twelve months to 30 June 2026: −$87.7M.
Trailing P/E: −6.1×; forward P/E: −5.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Neurogene, Inc. employs 131 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neurogene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Neurogene announced that its Compensation Committee approved non-qualified stock options for an aggregate of 8,340 shares of common stock, granted to five new employees on October 5, 2026, under Nasdaq Listing Rule 5635(c)(4).
Why it matters — The inducement grants indicate the company is adding new staff, which could signal ongoing operational expansion for NGNE.
Neurogene Inc. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, including a fireside chat and investor meetings. A live webcast of the fireside chat will be accessible.
Why it matters — The company's participation provides NGNE watchers an opportunity to hear from management and engage in investor meetings at a major investment conference.
Neurogene's Compensation Committee approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of common stock to two new employees on September 1, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).
Why it matters — NGNE watchers would care because this discloses a routine equity-based compensation action tied to hiring, which is a standard administrative disclosure rather than a reflection of company performance.
Neurogene (Nasdaq: NGNE) reported its second quarter 2026 financial results and highlighted recent corporate updates, including positive long-term Phase 1/2 data for its NGN-401 program that showed durable, multidomain developmental gains for patients with rare neurological diseases.
Why it matters — NGNE watchers will care because the reported Phase 1/2 data for NGN-401 suggest durable clinical progress in the company's lead program targeting rare neurological conditions.
Neurogene announced that its Compensation Committee approved inducent grants of non-qualified stock options to purchase an aggregate of 12,555 shares of common stock for four new employees, with a grant date of August 3, 2026, under Nasdaq Listing Rule 5635(c)(4).
Why it matters — NGNE watchers would care because inducement stock-option grants are a standard mechanism the company uses to attract and retain new hires, providing insight into its equity-compensation activity without signaling any change in its clinical or financial outlook.
The 9 Wall Street analysts covering Neurogene, Inc. have a median 12-month price target of $65, with estimates ranging from $46 to $166. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Neurogene, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurogene, Inc. 58 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Neurogene, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +145.3% from the last close, and Ticker Nerd's factor model ranks Neurogene, Inc. 58 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neurogene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGNE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $166 over the next 12 months.
Neurogene, Inc. returned +2.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases.
The most recent item we track (Business Wire, 5 Oct 2026): "Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Neurogene announced that its Compensation Committee approved non-qualified stock options for an aggregate of 8,340 shares of common stock, granted to five new employees on October 5, 2026, under Nasdaq Listing Rule 5635(c)(4).
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.
CEO Dr. Rachel L. McMinn Ph.D. · 131 employees · United States · https://www.neurogene.com
